Earnings summaries and quarterly performance for MAIA Biotechnology.
Executive leadership at MAIA Biotechnology.
Board of directors at MAIA Biotechnology.
Research analysts covering MAIA Biotechnology.
Recent press releases and 8-K filings for MAIA.
MAIA Biotechnology Highlights Ateganosine Clinical Program Progress at SITC 2025
MAIA
New Projects/Investments
- MAIA Biotechnology highlighted the ongoing momentum of its Ateganosine clinical program at SITC 2025, covering Phase 2 THIO-101 and Phase 3 THIO-104 clinical trials for non-small cell lung cancer (NSCLC).
- The company reported 12 patients enrolled in the Phase 2 THIO-101 expansion trial, with enrollment expanding to European Medicines Agency countries, Turkey, and Taiwan.
- Patient screening has also begun for the Phase 3 THIO-104 trial.
- Ateganosine holds Fast Track designation from the U.S. FDA for NSCLC.
- The Phase 2 THIO-101 trial has demonstrated an overall survival (OS) of 17.8 months to date, compared to approximately 6 months for current third-line NSCLC treatments, with one patient showing survival of 30 months (912 days) as of September 17, 2025.
Nov 21, 2025, 2:15 PM
MAIA Biotechnology Expands Phase 2 THIO-101 Study to Romania for NSCLC Treatment
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced on November 20, 2025, that it has initiated patient enrollment in Romania for the Phase 2 THIO-101 Part C study.
- This study evaluates ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC) patients.
- CEO Vlad Vitoc, M.D., highlighted observed 38% response rates with ateganosine treatment, significantly surpassing the up to 6% response rates of current treatments for this patient population.
- The expansion of the study to Romania aims to accelerate patient access and supports the company's strategy for accelerated approval in the U.S., following the FDA's Fast Track Designation received in July.
Nov 20, 2025, 2:00 PM
MAIA Biotechnology Announces Private Placement
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement involving the sale of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.52 per share.
- The private placement is expected to generate approximately $736,600 in gross proceeds.
- The company intends to use the net proceeds from the offering to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The closing of the private placement is anticipated on or about October 15, 2025.
Oct 14, 2025, 1:00 PM
MAIA Biotechnology Announces $736,600 Private Placement
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. has entered into definitive agreements for a private placement of 603,769 shares of common stock at a purchase price of $1.22 per share.
- Each share of common stock is offered with a warrant to purchase one share at an exercise price of $1.52 per share, exercisable six months after issuance for a term of three years.
- The offering is expected to generate approximately $736,600 in gross proceeds.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
Oct 13, 2025, 8:20 PM
MAIA Biotechnology announces digital asset treasury strategy
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced on October 7, 2025, the launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets.
- The company's Board of Directors has authorized holding up to 90% of its liquid assets in various cryptocurrencies.
- The initial cryptocurrencies approved for purchase and sale are Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC).
- This strategy aims to diversify the investment portfolio and create shareholder value for shareholders.
Oct 7, 2025, 12:58 PM
MAIA Biotechnology Initiates Digital Asset Treasury Strategy
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced on October 7, 2025, the launch of a new digital asset treasury strategy.
- The company's Board of Directors has authorized holdings of up to 90% of its liquid assets in cryptocurrencies.
- Corporate officers are authorized to purchase and sell Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) initially.
- The strategy aims to diversify the investment portfolio with leading crypto tokens, minimize risk, and create shareholder value.
Oct 7, 2025, 12:47 PM
MAIA Biotechnology Announces $2.25 Million Private Placement and Warrant Amendments
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement on September 29, 2025, expecting to raise approximately $2.25 million in gross proceeds.
- The private placement involves the sale of 1,733,766 shares of common stock at a purchase price of $1.30 per share, with each share accompanied by a warrant to purchase an additional share at an exercise price of $1.57.
- The net proceeds from this offering are intended to fund Step 1 of Part C of the Phase II trial THIO -101 and for working capital.
- Concurrently, the company amended existing common stock purchase warrants, originally issued on February 24, 2025, for 1,396,667 shares, reducing their exercise price from $1.87 per share to $1.30 per share.
Sep 30, 2025, 1:00 PM
MAIA Biotechnology awarded NIH grant for THIO-101 Phase 2 trial expansion
MAIA
New Projects/Investments
Product Launch
- MAIA Biotechnology, Inc. announced on September 24, 2025, that it was awarded a $2.3 million grant by the National Institutes of Health (NIH).
- This grant is for the expansion of its THIO-101 Phase 2 clinical trial, evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
- The $2.3 million NIH grant will be distributed over three years from 2025-2027 to support the enrollment of U.S. patients.
- As of June 30, 2025, the THIO-101 trial showed a median overall survival of 17.8 months for 22 patients, compared to 5 to 6 months for standard-of-care chemotherapy treatments.
Sep 24, 2025, 12:25 PM
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial
MAIA
New Projects/Investments
- MAIA Biotechnology, Inc. reported positive efficacy data from its THIO-101 Phase 2 clinical trial for ateganosine in patients with advanced non-small cell lung cancer (NSCLC).
- As of June 30, 2025, the estimated median progression-free survival (PFS) in third-line treatment was 5.6 months, which is more than double the standard of care PFS of 2.5 months.
- The estimated median overall survival (OS) was 17.8 months.
- The THIO-101 Phase 2 expansion trial began enrolling patients in July 2025.
Sep 11, 2025, 8:05 PM
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial
MAIA
New Projects/Investments
- MAIA Biotechnology announced positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine in patients with advanced non-small cell lung cancer (NSCLC).
- As of June 30, 2025, the estimated median progression-free survival (PFS) in third-line treatment was 5.6 months, which is more than double the standard of care PFS of 2.5 months, and the estimated median overall survival (OS) was 17.8 months.
- The data also indicated potential for extended dosing, with two patients completing 33 cycles of therapy, and a Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.
Sep 11, 2025, 1:28 PM
Quarterly earnings call transcripts for MAIA Biotechnology.